Opinion

Video

Treatment Sequencing Practices in Metastatic Urothelial Carcinoma

Author(s):

Elizabeth R. Plimack, MD, MS, FASCONeeraj Agarwal, MD

Focusing on metastatic urothelial carcinoma, the panel discusses the role of chemotherapy and outlines treatment sequencing approaches.

Related Videos
Rohan Garje, MD
Manmeet Ahluwalia, MD, MBA, FASCO
Mazyar Shadman, MD, MPH
Petros Grivas, MD, PhD; and Chandler Park, MD, MSc, FACP
Viktor Grünwald, MD, PhD
David A. Braun, MD, PhD, assistant professor, medicine (medical oncology), Louis Goodman and Alfred Gilman Yale Scholar, member, Center of Molecular and Cellular Oncology, Yale Cancer Center
Video 14 - "Key Takeaways in HER2-Mutated NSCLC"
Video 13 - "Treatment Considerations in HER2-Mutated NSCLC"
Sumanta Kumar Pal, MD, FASCO,
A panel of 5 experts on lung cancer
Related Content
Benjamin L. Maughan, MD, PharmD, of Huntsman Cancer Institute
June 11th 2024

Maughan Spotlights Ways to Reengage the Immune System and Debulking Approaches in RCC

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Benjamin L. Maughan, MD, PharmD
June 7th 2024

Notable RCC Data Presented at ASCO May Shed Light on Key Biomarkers and Combination Approaches

Carrie L. Kitko, MD, associate professor, pediatrics, medical director, the Pediatric Stem Cell Transplantation Program, the Ingram Professor of Pediatric Oncology, Monroe Carell Jr. Children’s Hospital at Vanderbilt; Sagar S. Patel, MD, director, Communications and Media Relationships, the Division of Hematology, the University of Utah Huntsman Cancer Institute
February 19th 2024

Kitko and Patel Emphasize the Importance of GVHD Research and Awareness

Benjamin L. Maughan, MD, PharmD
June 6th 2024

Advancements With Combination Therapies in RCC Usher in New Questions

Brian Rini, MD
June 5th 2024

Higher T-Cell Inflamed GEP Values Are Positively Associated with Outcomes For Pembrolizumab/Axitinib in ccRCC